Tags

Type your tag names separated by a space and hit enter

Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19.
Int J Mol Sci. 2022 Jul 25; 23(15)IJ

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major public health challenge worldwide. Owing to the emergence of novel viral variants, the risks of reinfections and vaccine breakthrough infections has increased considerably despite a mass of vaccination. The formation of cytokine storm, which subsequently leads to acute respiratory distress syndrome, is the major cause of mortality in patients with COVID-19. Based on results of preclinical animal models and clinical trials of acute lung injury and acute respiratory distress syndrome, the immunomodulatory, tissue repair, and antiviral properties of MSCs highlight their potential to treat COVID-19. This review article summarizes the potential mechanisms and outcomes of MSC therapy in COVID-19, along with the pathogenesis of the SARS-CoV-2 infection. The properties of MSCs and lessons from preclinical animal models of acute lung injury are mentioned ahead. Important issues related to the use of MSCs in COVID-19 are discussed finally.

Authors+Show Affiliations

Department of Pathology, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 402, Taiwan.Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 402, Taiwan. Department of Pediatrics, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.Department of Pathology, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Pathology, Chung Shan Medical University Hospital, Taichung 402, Taiwan.Department of Pathology, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Pathology, Chung Shan Medical University Hospital, Taichung 402, Taiwan.Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 402, Taiwan. Department of Pediatrics, School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan. Department of Clinical Pathology, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

35897770

Citation

Li, Ju-Pi, et al. "Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19." International Journal of Molecular Sciences, vol. 23, no. 15, 2022.
Li JP, Wu KH, Chao WR, et al. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19. Int J Mol Sci. 2022;23(15).
Li, J. P., Wu, K. H., Chao, W. R., Lee, Y. J., Yang, S. F., & Chao, Y. H. (2022). Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19. International Journal of Molecular Sciences, 23(15). https://doi.org/10.3390/ijms23158196
Li JP, et al. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19. Int J Mol Sci. 2022 Jul 25;23(15) PubMed PMID: 35897770.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19. AU - Li,Ju-Pi, AU - Wu,Kang-Hsi, AU - Chao,Wan-Ru, AU - Lee,Yi-Ju, AU - Yang,Shun-Fa, AU - Chao,Yu-Hua, Y1 - 2022/07/25/ PY - 2022/07/12/received PY - 2022/07/23/accepted PY - 2022/7/28/entrez PY - 2022/7/29/pubmed PY - 2022/7/30/medline KW - COVID-19 KW - acute lung injury KW - acute respiratory distress syndrome KW - cell therapy KW - mesenchymal stem cells JF - International journal of molecular sciences JO - Int J Mol Sci VL - 23 IS - 15 N2 - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major public health challenge worldwide. Owing to the emergence of novel viral variants, the risks of reinfections and vaccine breakthrough infections has increased considerably despite a mass of vaccination. The formation of cytokine storm, which subsequently leads to acute respiratory distress syndrome, is the major cause of mortality in patients with COVID-19. Based on results of preclinical animal models and clinical trials of acute lung injury and acute respiratory distress syndrome, the immunomodulatory, tissue repair, and antiviral properties of MSCs highlight their potential to treat COVID-19. This review article summarizes the potential mechanisms and outcomes of MSC therapy in COVID-19, along with the pathogenesis of the SARS-CoV-2 infection. The properties of MSCs and lessons from preclinical animal models of acute lung injury are mentioned ahead. Important issues related to the use of MSCs in COVID-19 are discussed finally. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/35897770/Immunomodulation_of_Mesenchymal_Stem_Cells_in_Acute_Lung_Injury:_From_Preclinical_Animal_Models_to_Treatment_of_Severe_COVID_19_ DB - PRIME DP - Unbound Medicine ER -